NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 135 filers reported holding NEKTAR THERAPEUTICS in Q4 2013. The put-call ratio across all filers is 0.98 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $28,601 | -65.7% | 44,970 | +22.0% | 0.00% | – |
| Q4 2022 | $83,274 | +54.2% | 36,847 | +120.0% | 0.00% | – |
| Q3 2022 | $54,000 | -99.4% | 16,750 | -81.2% | 0.00% | -100.0% |
| Q1 2018 | $9,462,000 | +64.2% | 89,050 | -83.1% | 0.01% | +42.9% |
| Q3 2015 | $5,764,000 | +0.3% | 525,938 | +14.5% | 0.01% | +16.7% |
| Q2 2015 | $5,745,000 | +13.3% | 459,193 | +40.4% | 0.01% | 0.0% |
| Q4 2014 | $5,070,000 | +31.8% | 327,120 | +2.6% | 0.01% | +50.0% |
| Q3 2014 | $3,848,000 | -2.7% | 318,773 | +3.4% | 0.00% | -20.0% |
| Q2 2014 | $3,953,000 | +197.0% | 308,362 | +180.7% | 0.01% | +150.0% |
| Q1 2014 | $1,331,000 | +38.4% | 109,841 | +29.6% | 0.00% | +100.0% |
| Q4 2013 | $962,000 | +15.6% | 84,730 | +6.5% | 0.00% | 0.0% |
| Q3 2013 | $832,000 | -3.4% | 79,590 | +6.8% | 0.00% | 0.0% |
| Q2 2013 | $861,000 | – | 74,530 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TIRSCHWELL & LOEWY INC | 588,908 | $7,138,000 | 1.23% |
| Granahan Investment Management | 3,693,956 | $44,771,000 | 1.21% |
| NEA Management Company, LLC | 1,825,600 | $22,126,000 | 1.09% |
| FIC CAPITAL INC | 150,868 | $1,829,000 | 0.75% |
| Rhenman & Partners Asset Management AB | 181,797 | $2,203,000 | 0.66% |
| SOPHROSYNE CAPITAL LLC | 60,200 | $728,000 | 0.64% |
| HARVEY CAPITAL MANAGEMENT INC | 130,400 | $1,580,000 | 0.63% |
| Artal Group S.A. | 1,300,000 | $15,756,000 | 0.57% |
| BOGLE INVESTMENT MANAGEMENT L P /DE/ | 564,418 | $6,840,000 | 0.47% |
| OppenheimerFunds, Inc. | 24,400,000 | $295,728,000 | 0.35% |